Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service CSF shunts cases in Pennsylvania: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 10% on average (47 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 391 | 47% |
| 2020 | 3 | 284 | 49% |
| 2021 | 2 | 298 | 51% |
| 2022 | 2 | 299 | 53% |
| 2023 | 3 | 293 | 56% |
| 2024 | 2 | 238 | 58% |
| 2025 from claims | – | 277 224–325 | 59% |
| 2026 forecast | – | 281 220–353 | 59% |
| 2027 forecast | – | 281 208–371 | 59% |
| 2028 forecast | – | 281 199–388 | 60% |
| 2029 forecast | – | 281 191–403 | 60% |
| 2030 forecast | – | 281 184–418 | 61% |
Ventriculoperitoneal shunt placement and revision, including normal-pressure hydrocephalus. Professional codes (what the surgeon bills): CPT 62223, 62230.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Pennsylvania; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 6 | 455−4%/yr | −4%/yr | 0.2 | 0% | 600 in 2030+4.8%/yr |
| Massachusetts | 5 | 193−8.4%/yr | −8.4%/yr | 0.2 | 0% | 220 in 2030+1.9%/yr |
| New Jersey | 0 | 134−11%/yr | −11%/yr | 0.1 | 0% | 120 in 2030−1.3%/yr |
| Connecticut | 1 | 129+5.9%/yr | +5.9%/yr | 0.4 | 0% | 250 in 2030+12%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Aneurysm & intracranial embolization | 29 | 803+20%/yr | +20%/yr | 0.61.1× | 0% | 1,470 in 2030+11%/yr |
| Stroke thrombectomy | 30 | 767+7.4%/yr | +7.4%/yr | 0.61.5× | 0% | 1,030 in 2030+5%/yr |
| DBS & VNS | 4 | 485−4.3%/yr | −4.3%/yr | 0.31.5× | 0% | 620 in 2030+4.1%/yr |
CSF shunts in every state, and its device makers · Every procedure market in Pennsylvania · Every state · Compare with New York
Johnson & Johnson MedTech leads with 49% of company spending on these surgeons in 2025, −23 pts on 2024.
In 2025, 7 companies reported engagement with Pennsylvania’s surgeons worth $136K in consulting, speaking, meals and travel tied to these products, about $68K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 4 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.